Drugs / GNR-060
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05601999 | Sep 2021 → May 2024 | ST-elevation myocardial infarction | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601999 ↗ |
| Modality | Protein / enzyme biologic | “GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse.” NCT05601999 ↗ |
| Route | Intravenous | “GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus” NCT05601999 ↗ |